Truffle’s recipe for company creation

Truffle Capital plans to deploy €250M fund to scour the U.S., Europe for IP to build biotechs, medtechs

Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing.

The fund will channel around 30% of its capital into drug development and 70% into medtech across 10 to 12 companies, mostly in France. Individual investments

Read the full 543 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE